Table 1.
Prematch Patient Demographics and Clinical Characteristics
| Demographics and clinical characteristics | IVIG cohort (N = 986) | SCIG cohort (N = 653) | P value |
|---|---|---|---|
| Age, mean,a yrs (SD) | 49.1 (± 20.15) | 40.3 (± 38.7) | <.001 |
| Age-groupa | |||
| 0–20, yrs (%) | 155 (15.72) | 178 (27.26) | <.001 |
| 21–30, yrs (%) | 26 (2.64) | 60 (9.19) | <.001 |
| 31–40, yrs (%) | 77 (7.81) | 58 (8.88) | <.001 |
| 41–50, yrs (%) | 134 (13.59) | 90 (13.78) | <.001 |
| 51–60, yrs (%) | 285 (28.90) | 134 (20.52) | <.001 |
| 61–70, yrs (%) | 224 (22.72) | 103 (15.77) | <.001 |
| ≥71, yrs (%) | 85 (8.62) | 30 (4.59) | <.001 |
| Sexa | |||
| Female, N (%) | 575 (58.32) | 412 (63.09) | .049 |
| Male, N (%) | 411 (41.68) | 241 (36.91) | .049 |
| Charlson Comorbidity Index score | |||
| Mean score,a N (SD) | 3.01 (± 2.73) | 1.74 (± 1.91) | <.001 |
| Elixhauser conditions (comorbidities) | |||
| Congestive heart failure,a N (%) | 68 (6.90) | 16 (2.45) | <.001 |
| Arrythmia,a N (%) | 167 (16.94) | 39 (5.97) | <.001 |
| Valvular disease,a N (%) | 84 (8.52) | 19 (2.91) | <.001 |
| Pulmonary circulation disorder,a N (%) | 44 (4.46) | 17 (2.60) | .052 |
| Peripheral vascular disorders,a N (%) | 46 (4.67) | 15 (2.30) | .013 |
| Hypertension, uncomplicated,a N (%) | 328 (33.27) | 133 (20.37) | <.001 |
| Hypertension, complicated,a N (%) | 44 (4.46) | 15 (2.30) | .021 |
| Paralysis, N (%) | 12 (1.22) | 10 (1.53) | .588 |
| Other neurologic disorders, N (%) | 79 (8.01) | 42 (6.43) | .231 |
| Chronic obstructive pulmonary disease, N (%) | 458 (46.45) | 320 (49.00) | .311 |
| Diabetes, uncomplicated,a N (%) | 144 (14.60) | 60 (9.19) | .001 |
| Diabetes, complicated,a N (%) | 36 (3.65) | 12 (1.84) | .003 |
| Hypothyroid, N (%) | 144 (14.60) | 88 (13.48) | .521 |
| Renal failure,a N (%) | 58 (5.88) | 17 (2.60) | .002 |
| Liver disease,a N (%) | 58 (5.88) | 13 (1.99) | <.001 |
| Peptic ulcer disease, excluding bleeding, N (%) | 6 (0.61) | 2 (0.31) | .390 |
| AIDS/HIV, N (%) | 3 (0.30) | 2 (0.31) | .994 |
| Lymphoma,a N (%) | 180 (18.26) | 21 (3.22) | <.001 |
| Metastatic cancer,a N (%) | 24 (2.43) | 3 (0.46) | .002 |
| Solid tumor without metastasis,a N (%) | 77 (7.81) | 17 (2.60) | <.001 |
| Rheumatoid arthritis/collagen, N (%) | 126 (12.78) | 73 (11.18) | .332 |
| Coagulopathy,a N (%) | 109 (11.05) | 23 (3.52) | <.001 |
| Obesity, N (%) | 48 (4.87) | 27 (4.13) | .487 |
| Weight loss,a N (%) | 70 (7.10) | 15 (2.30) | <.001 |
| Fluid and electrolyte disorders,a N (%) | 191 (19.37) | 57 (8.73) | <.001 |
| Blood-loss anemia, N (%) | 9 (0.91) | 5 (0.77) | .751 |
| Deficiency anemia, N (%) | 73 (7.40) | 42 (6.43) | .451 |
| Alcohol abuse, N (%) | 3 (0.30) | 3 (0.46) | .612 |
| Drug abuse, N (%) | 12 (1.22) | 7 (1.07) | .788 |
| Psychoses, N (%) | 24 (2.43) | 5 (0.77) | .121 |
| Depression, N (%) | 175 (17.75) | 94 (14.40) | .073 |
a
Significant difference.
IVIG indicates intravenous immunoglobulin; SCIG, subcutaneous immunoglobulin; SD, standard deviation.